COVID, FDA and vaccines
Digest more
FDA announces cucumber recall
Digest more
Alzheimer's blood test approved by FDA
Digest more
The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials.
The US Food and Drug Administration will now require Covid-19 vaccines from Pfizer/BioNTech and Moderna to use expanded warning labels with more information about the risk of a rare heart condition after vaccination.
"The Trump administration is proposing a $6.8 billion budget for the FDA, including $3.2 billion in budget authority and 3.6 billion in user fees for fiscal year 2026," Makary told a U.S. Senate panel.
Explore more
The FDA warns that longtime users of popular allergy medications may experience "severe itching" after stopping use.
Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy
The Trump administration is proposing a $6.8 billion budget request for the U.S. Food and Drug Administration for the 2026 fiscal year, Commissioner of Food and Drugs Martin Makary said on Thursday.
An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic castration-resistant prostate cancer (mCRPC).
The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in the United States have come to rely on.